Mid
R
RCUSAI Stock Diagnostic Report
Arcus Biosciences slides 20% on stock offering, kidney-cancer data
After the stock offering and renal cancer clinical data were released, Arcus Biosciences' stock price fell by 20%.
View Source Article ↗
AI CATALYST SCORE45 / 100Score computed by Sentinel V12
REFERENCE PRICENot measuredReference entry price at analysis time
+ANALYSIS HISTORY
RCUS Analysis History (Last 30 Days)